Millions of Americans suffer from dry eye, compromising ocular surface health and comfort. While dry eye has many causes, a significant number of cases are linked to decreased production of fluid and protein by the lacrimal gland (LG). Some of the most severe dry eye cases are associated with Sjgren's syndrome (SS), an autoimmune disease with lymphocytic infiltration of LG and salivary glands, alterations in volume and composition of exocrine secretions, and increased risk of B-cell lymphoma. While SS-associated dry eye affects 0.4-0.8% of the population, the mechanisms responsible for its initiation and progression are poorly understood. Therapies for SS-associated dry eye that move beyond management of symptoms to address the underlying LG inflammation and pathological changes in tear composition are simply not available. LG acinar cells (LGAC) produce and secrete most tear proteins, while the sorting of newly-synthesized tear proteins into secretory vesicles is governed by many effectors including Rabs, small membrane-associated GTPases. LGAC secretory vesicles are enriched in Rab3D, Rab27a and Rab27b, with their abundance varying across individual vesicles. Changes in Rab abundance on secretory vesicles may reflect differences in content, due to differing contributions of these Rabs in mediating traffic from distinct compartments of origin. Using knockout mouse strains, we have linked Rab27a and Rab27b to secretion of tear cathepsin S (CTSS). A potent lysosomal protease, CTSS has roles in antigen presentation, extracellular matrix remodeling and inflammation; we have found that CTSS is significantly elevated in tears and LG of a mouse model of SS and in tears of SS patients. We HYPOTHESIZE that 1) Tear CTSS is highly regulated through its trafficking via a novel Rab27-mediated pathway from lysosomes to SV; and 2) Exposure of the LG to inflammatory cytokines may elevate tear CTSS by increasing its expression in LG and/or by altering the expression/activity of secretory Rabs. Finally, increased tear and LG CTSS activity may promote the ocular surface inflammation and autoimmune dacryoadenitis that characterize SS-associated dry eye.
Three AIMS are proposed: 1) Characterize the pathways responsible for sorting of CTSS into secretory vesicles in LGAC; 2) Determine how pro-inflammatory cytokines affect CTSS sorting and release from secretory vesicles in LGAC; and 3) Determine whether increased tear and LG CTSS drive ocular surface inflammation and autoimmune dacryoadenitis. These studies will utilize cultured LGAC for in vitro analysis of Rab function, including LGAC cultured from Rab knockout mice, using confocal fluorescence and super-resolution microscopy, analysis of protein secretion, and molecular analysis of gene expression, with and without exposure to pro-inflammatory cytokines. They will also utilize the male NOD mouse model of SS-associated dry eye to assess the ability of CTSS inhibitor to reduce signs of disease. Completion of these AIMS will 1) Define mechanisms underlying increased tear CTSS activity in SS patients; and 2) Determine if CTSS actively drives SS-associated dry eye.

Public Health Relevance

Sjgren's syndrome, which affects millions of Americans, is characterized by systemic autoimmunity and subsequent loss of function of exocrine glands, such as the lacrimal gland, resulting in aqueous-deficient dry eye. The proposed renewal grant will characterize the processes in the lacrimal gland responsible for sorting tear proteins into secretory vesicles released in response to diverse stimuli, and in particular determine how changes in expression and release of a particular protein, cathepsin S, from lacrimal gland may contribute to the development and progression of Sjgren's syndrome. Knowledge obtained from these studies will be critical in understanding the mechanisms responsible for this debilitating disease, and in developing new treatment strategies.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY011386-18
Application #
9511830
Study Section
Diseases and Pathophysiology of the Visual System Study Section (DPVS)
Program Officer
Mckie, George Ann
Project Start
1996-07-01
Project End
2021-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
18
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Southern California
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Hawley, Dillon; Tang, Xin; Zyrianova, Tatiana et al. (2018) Myoepithelial cell-driven acini contraction in response to oxytocin receptor stimulation is impaired in lacrimal glands of Sjögren's syndrome animal models. Sci Rep 8:9919
Ju, Yaping; Janga, Srikanth Reddy; Klinngam, Wannita et al. (2018) NOD and NOR mice exhibit comparable development of lacrimal gland secretory dysfunction but NOD mice have more severe autoimmune dacryoadenitis. Exp Eye Res 176:243-251
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Klinngam, Wannita; Fu, Runzhong; Janga, Srikanth R et al. (2018) Cathepsin S Alters the Expression of Pro-Inflammatory Cytokines and MMP-9, Partially through Protease-Activated Receptor-2, in Human Corneal Epithelial Cells. Int J Mol Sci 19:
Janga, Srikanth R; Shah, Mihir; Ju, Yaping et al. (2018) Longitudinal analysis of tear cathepsin S activity levels in male non-obese diabetic mice suggests its potential as an early stage biomarker of Sjögren's Syndrome. Biomarkers :1-12
Edman, Maria C; Janga, Srikanth R; Meng, Zhen et al. (2018) Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients. Sci Rep 8:11044
Meng, Zhen; Klinngam, Wannita; Edman, Maria C et al. (2017) Interferon-? treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome. PLoS One 12:e0184781
Aluri, Hema S; Samizadeh, Mahta; Edman, Maria C et al. (2017) Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Tear Production in a Mouse Model of Sjögren's Syndrome. Stem Cells Int 2017:3134543
Shah, Mihir; Edman, Maria C; Reddy Janga, Srikanth et al. (2017) Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome. Invest Ophthalmol Vis Sci 58:372-385
Meng, Zhen; Edman, Maria C; Hsueh, Pang-Yu et al. (2016) Imbalanced Rab3D versus Rab27 increases cathepsin S secretion from lacrimal acini in a mouse model of Sjögren's Syndrome. Am J Physiol Cell Physiol 310:C942-54

Showing the most recent 10 out of 75 publications